THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME

Aim. To assess the role of the activation of matrix metalloproteinase-1 zymogen (ProMMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the development of left ventricular (LV) hypertrophy in patients with arterial hypertension (HT) and metabolic syndrome (MS) with varying degree of obesi...

Full description

Saved in:
Bibliographic Details
Main Authors: A. N. Zakirova, E. Z. Fatkullina, N. E. Zakirova
Format: Article
Language:English
Published: Столичная издательская компания 2015-09-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/135
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849228040335261696
author A. N. Zakirova
E. Z. Fatkullina
N. E. Zakirova
author_facet A. N. Zakirova
E. Z. Fatkullina
N. E. Zakirova
author_sort A. N. Zakirova
collection DOAJ
description Aim. To assess the role of the activation of matrix metalloproteinase-1 zymogen (ProMMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the development of left ventricular (LV) hypertrophy in patients with arterial hypertension (HT) and metabolic syndrome (MS) with varying degree of obesity.Material and methods. 108 patients with HT and MS divided into 3 groups according to body mass index, and 28 healthy women were studied. Intracardiac blood flow and ProMMP-1 and TIMP-1 levels were assessed.Results. Disbalance in the ProMMP-1 and TIMP-1 systems  is associated with the severity of left ventricular remodeling and grade of obesity. The changes in LV structure and geometry and activation ProMMP-1 with a deficit of TIMP-1 were most significant in patients with HT and grade 3 obesity (respectively 7.7±0.61 and 183.6±17.2 ng/ml in grade 3 obesity vs 3.5±0.3 and 291.7±22.4 ng/ml in grade 1 obesity; p<0.05). Associations between hemodynamic parameters and levels of ProMMP-1 [withLVmass index (LVMI): r=0.47; p<0.05] and TIMP-1 (with LVMI: r=-0.39;  p<0.05) were determined.Conclusion. Changes in the ProMMP-1 and TIMP-1 system in women with HT and MS are associated with the severity ofLVhypertrophy.
format Article
id doaj-art-baa5dea27a4c4e13ae582326cc3795ca
institution Kabale University
issn 1819-6446
2225-3653
language English
publishDate 2015-09-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj-art-baa5dea27a4c4e13ae582326cc3795ca2025-08-23T10:00:16ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-01101374210.20996/1819-6446-2014-10-1-37-42134THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROMEA. N. Zakirova0E. Z. Fatkullina1N. E. Zakirova2Bashkir State Medical University, UfaBashkir State Medical University, UfaBashkir State Medical University, UfaAim. To assess the role of the activation of matrix metalloproteinase-1 zymogen (ProMMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the development of left ventricular (LV) hypertrophy in patients with arterial hypertension (HT) and metabolic syndrome (MS) with varying degree of obesity.Material and methods. 108 patients with HT and MS divided into 3 groups according to body mass index, and 28 healthy women were studied. Intracardiac blood flow and ProMMP-1 and TIMP-1 levels were assessed.Results. Disbalance in the ProMMP-1 and TIMP-1 systems  is associated with the severity of left ventricular remodeling and grade of obesity. The changes in LV structure and geometry and activation ProMMP-1 with a deficit of TIMP-1 were most significant in patients with HT and grade 3 obesity (respectively 7.7±0.61 and 183.6±17.2 ng/ml in grade 3 obesity vs 3.5±0.3 and 291.7±22.4 ng/ml in grade 1 obesity; p<0.05). Associations between hemodynamic parameters and levels of ProMMP-1 [withLVmass index (LVMI): r=0.47; p<0.05] and TIMP-1 (with LVMI: r=-0.39;  p<0.05) were determined.Conclusion. Changes in the ProMMP-1 and TIMP-1 system in women with HT and MS are associated with the severity ofLVhypertrophy.https://www.rpcardio.online/jour/article/view/135matrix metalloproteinasesleft ventricular hypertrophyarterial hypertensionmetabolic syndrome
spellingShingle A. N. Zakirova
E. Z. Fatkullina
N. E. Zakirova
THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
Рациональная фармакотерапия в кардиологии
matrix metalloproteinases
left ventricular hypertrophy
arterial hypertension
metabolic syndrome
title THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
title_full THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
title_fullStr THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
title_full_unstemmed THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
title_short THE ROLE OF THE MATRIX METALLOPROTEINASES IN THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
title_sort role of the matrix metalloproteinases in the development of left ventricular hypertrophy in patients with arterial hypertension and metabolic syndrome
topic matrix metalloproteinases
left ventricular hypertrophy
arterial hypertension
metabolic syndrome
url https://www.rpcardio.online/jour/article/view/135
work_keys_str_mv AT anzakirova theroleofthematrixmetalloproteinasesinthedevelopmentofleftventricularhypertrophyinpatientswitharterialhypertensionandmetabolicsyndrome
AT ezfatkullina theroleofthematrixmetalloproteinasesinthedevelopmentofleftventricularhypertrophyinpatientswitharterialhypertensionandmetabolicsyndrome
AT nezakirova theroleofthematrixmetalloproteinasesinthedevelopmentofleftventricularhypertrophyinpatientswitharterialhypertensionandmetabolicsyndrome
AT anzakirova roleofthematrixmetalloproteinasesinthedevelopmentofleftventricularhypertrophyinpatientswitharterialhypertensionandmetabolicsyndrome
AT ezfatkullina roleofthematrixmetalloproteinasesinthedevelopmentofleftventricularhypertrophyinpatientswitharterialhypertensionandmetabolicsyndrome
AT nezakirova roleofthematrixmetalloproteinasesinthedevelopmentofleftventricularhypertrophyinpatientswitharterialhypertensionandmetabolicsyndrome